Tag: synagis market growth

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Synagis Market Expansion Outlook: What Revenue Opportunities Are Ahead?

The expansion observed during the past period was a result of an increased occurrence of RSV infections in infants, coupled with a growing awareness of preventive monoclonal therapies, the enlargement of neonatal intensive care units, the availability of reimbursement for RSV prophylaxis, and regulatory approvals for pediatric biologics.

The projected growth during this period stems from increased funding in advanced RSV prevention treatments, a heightened focus on long-acting monoclonal antibody solutions, the expansion of facilities for biologic manufacturing, an uptick in pediatric healthcare spending, and the broader implementation of precise immunotherapy methods.

Significant trends expected in the forecast timeframe include the wider use of monoclonal antibody-based RSV prophylactic measures, an increasing emphasis on preventive immunotherapies for children, the broadening of distribution networks for biologics requiring cold-chain storage, a heightened focus on safeguarding high-risk infants, and enhanced manufacturing scalability for biologic products.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=37727740&type=smp&name=Synagis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Synagis Market Growth Factors Behind Sustained Expansion

The increasing prevalence of chronic respiratory conditions is projected to fuel the expansion of the **synagis market** going forward. Chronic respiratory conditions are protracted illnesses that affect the lungs and airways, leading to persistent breathing difficulties. The incidence of these conditions can be attributed to multiple elements, including an aging demographic, choices related to smoking and lifestyle, genetic and occupational factors, and environmental pollution. Synagis (palivizumab) serves to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and children, thereby diminishing complications and exacerbations in those afflicted with chronic respiratory conditions. For instance, in June 2025, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that chronic respiratory diseases affect over 80 million people, with many more cases undiagnosed, according to a new WHO and European Respiratory Society report. Consequently, the rising prevalence of chronic respiratory conditions is propelling the growth of the **synagis market**. Synagis Market Driver: Impact Of Increasing Healthcare Expenditure On The Growth Of The Market

Synagis Market Segment Landscape: Which Areas Lead Development?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

Synagis Market Industry Trends Fueling Future Revenue Growth

Companies active in the Synagis market are concentrating on securing drug approvals to deliver preventive solutions for respiratory syncytial virus (RSV), thereby addressing a considerable unmet medical requirement. Drug approval is a regulatory procedure where authorities assess a drug’s safety, efficacy, and quality, based on clinical trial data, before authorizing its use. For example, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical entity, received clearance from the Central Drugs Standard Control Organisation (CDSCO) to commercialize palivizumab, which offers preventive therapy for RSV. This injectable formulation is provided as palivizumab 100 mg/ml in single-dose vials of 50 mg/0.5 ml and 100 mg/ml, intended for intramuscular administration. Palivizumab is prescribed for infants born at =35 weeks gestation, children who require management for bronchopulmonary dysplasia (BPD), and those diagnosed with hemodynamically significant congenital heart disease (CHD). This approval signifies the inaugural preventive therapy for RSV made accessible in India.

Synagis Market Industry Leaders And Competitive Landscape

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

View The Full Synagis Market Report:

https://thebusinessresearchcompany.com/report/synagis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Synagis Market Top Region: Where Does Most Revenue Come From?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Synagis Market Revenue Growth Supported By A CAGR Of % Through 2030

Growth during the historical period was driven by a rising number of RSV infections affecting infants, heightened awareness around preventive monoclonal antibody treatments, the expansion of neonatal intensive care units, the presence of reimbursement policies for RSV prophylaxis, and the regulatory clearance of pediatric biologic drugs.

The expansion anticipated during the forecast period is driven by greater funding for novel RSV prevention treatments, a heightened emphasis on long-acting monoclonal antibodies, the scaling up of biologic production capabilities, rising spending on children’s healthcare, and the growing uptake of precision immunotherapy methods. Key developments shaping this period encompass the broader use of monoclonal antibody-based RSV prevention, an increased focus on prophylactic pediatric immunotherapies, the growth of cold-chain reliant biologic delivery systems, a stronger priority on protecting high-risk infants, and enhancements in the scalable manufacturing of biologics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Synagis Market Industry Drivers: What Is Driving Revenue Growth?

The synagis market is anticipated to experience growth driven by the rising incidence of chronic respiratory conditions. These conditions, which are long-term ailments affecting the lungs and airways and causing persistent breathing difficulties, are becoming more common. Their increased prevalence is linked to various influences such as the aging population, lifestyle choices like smoking, genetic predispositions, occupational exposures, and environmental pollution. Synagis, also known as palivizumab, is used to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and children, thereby helping to reduce complications and exacerbations for those already dealing with chronic respiratory issues. A report from the World Health Organization (WHO) and the European Respiratory Society, as noted in June 2025 by the Switzerland-based UN agency, indicated that chronic respiratory diseases impact over 80 million individuals, with many more cases remaining undiagnosed. This growing prevalence of chronic respiratory conditions is therefore a key factor fueling the expansion of the synagis market.

The synagis market is being significantly propelled forward by the observed increase in healthcare spending. Healthcare expenditure encompasses all financial resources allocated to the delivery of health services, encompassing medical treatments, hospital stays, medications, and preventive efforts. Several factors contribute to this rise in spending, including a growing elderly population, a higher incidence of chronic diseases, public health emergencies, and an escalating demand for various services. This increase in financial resources is paving the way for greater investment in preventive therapies for vulnerable populations, such as high-risk infants and young children. As healthcare budgets expand, a larger portion of funding is being directed towards medications like synagis, which are used to prevent severe respiratory illnesses. Data from the Office for National Statistics, a UK government department, highlighted in May 2024 that total healthcare expenditure experienced a 5.6% nominal increase between 2022 and 2023, a significant contrast to the 0.9% growth seen in 2022. This upward trend in healthcare expenditure is thus a major driver behind the growth of the synagis market.

Synagis Market Segment Outlook: Which Categories Are Expanding The Fastest?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

#Synagis Market Growth Trends: What Is Influencing The Future Outlook?

Key industry players in the Synagis market are actively pursuing drug approvals to deliver preventive treatments for respiratory syncytial virus (RSV), thereby tackling a critical unmet medical need. Drug approval involves a regulatory process where authorities assess a medication’s safety, effectiveness, and quality through clinical trial evidence prior to granting authorization for commercial use. For example, in September 2023, AstraZeneca Pharma India Ltd., a biopharmaceutical firm based in India, received approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventive approach for RSV. This injectable product is supplied as palivizumab 100 mg/ml in single-dose vials containing 50 mg/0.5 ml and 100 mg/ml formulations, designed for intramuscular delivery. Palivizumab is recommended for infants born at or before 35 weeks of gestation, children undergoing treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This regulatory endorsement marks the first RSV preventive therapy to be made accessible in India.

Synagis Market Key Companies And Competitive Benchmarking

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Access The Complete Synagis Market Report:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Synagis Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Synagis Market By 2030 Based On Its 2026 Value?

The historical growth stemmed from a rise in RSV infections among infants, accompanied by an expanding understanding of preventive monoclonal therapies. Further contributions came from the enlargement of neonatal intensive care units, the availability of reimbursement for RSV prevention, and the acquisition of regulatory approvals for pediatric biologics.

During the projected timeframe, an uplift in growth is expected, stemming from increased capital allocation towards advanced RSV prevention treatments, a heightened emphasis on extended-duration monoclonal antibodies, the enlargement of biologic production capabilities, a rise in spending on pediatric healthcare, and a wider embrace of precise immunotherapy strategies.

Key developments anticipated in the forecast period involve a growing acceptance of monoclonal antibody-based RSV prophylaxis, an intensifying focus on pediatric immunotherapies for prevention, the broadening of distribution networks for biologics requiring cold-chain management, an increasing priority placed on protecting high-risk infants, and enhanced scalability in the manufacturing of biologics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

What Are The Main Drivers Accelerating The Growth Of The Synagis Market?

The increasing occurrence of chronic respiratory conditions is anticipated to stimulate the growth of the synagis market. Chronic respiratory conditions are prolonged ailments that affect the lungs and airways, leading to continuous breathing issues. The prevalence of these conditions can be attributed to several factors, including an aging population, lifestyle choices and smoking, genetic and occupational influences, and environmental pollution. Synagis (palivizumab) works to prevent severe respiratory syncytial virus (RSV) infections in at-risk infants and children, thereby reducing complications and exacerbations in those with chronic respiratory conditions. For instance, in June 2025, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that chronic respiratory diseases impact more than 80 million individuals, with many more undiagnosed, according to a new WHO and European Respiratory Society report. Thus, the rising prevalence of chronic respiratory conditions is driving the expansion of the synagis market.

How Is The Synagis Market Structured Across Different Market Segments?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

What Trends Are Impacting The Synagis Market?

Within the Synagis market, leading companies are prioritizing securing drug approvals to offer preventive treatment for respiratory syncytial virus (RSV), thereby addressing a considerable gap in medical care. This approval process involves regulatory bodies assessing a drug’s safety, effectiveness, and quality, drawing on clinical trial findings prior to its authorization for patient use. An illustration of this trend is AstraZeneca Pharma India Ltd., an India-based biopharmaceutical firm, which in September 2023, received authorization from the Central Drugs Standard Control Organisation (CDSCO) to commercialize palivizumab, a preventive treatment for RSV. This injectable medication, palivizumab, is supplied as 100 mg/ml in individual-dose vials of 50 mg/0.5 ml and 100 mg/ml, intended for intramuscular administration. Its indications include infants delivered at =35 weeks gestation, children needing therapy for bronchopulmonary dysplasia (BPD), and individuals with hemodynamically significant congenital heart disease (CHD). Significantly, this marks the introduction of the first preventive therapy for RSV in India.

Which Industry Players Are Present In The Synagis Market?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Access The Complete Synagis Market Report:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

Which Region Contributes The Most To The Synagis Market?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Synagis Market Expected To Reach Based On Its 2026 Value?

The historical period’s growth stemmed from a heightened occurrence of RSV infections among infants, an escalating understanding of preventative monoclonal treatments, the broader availability of neonatal intensive care facilities, the provision of financial coverage for RSV prevention, and the authorization of pediatric biological agents.

Anticipated growth during the forecast period is fueled by increasing investments in advanced RSV prevention therapies, a heightened focus on long-acting monoclonal antibodies, the expansion of biologic manufacturing capacity, rising pediatric healthcare expenditure, and the wider adoption of precision immunotherapy approaches. Furthermore, significant trends in this period include the growing embrace of monoclonal antibody-based RSV prophylaxis, an intensifying focus on preventive pediatric immunotherapies, the broadening of cold-chain dependent biologic distribution, an increased emphasis on protecting high-risk infants, and enhanced manufacturing scalability for biologics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

Which Drivers Are Supporting The Synagis Market Growth?

The increasing occurrence of chronic respiratory conditions is anticipated to stimulate the growth of the synagis market. Chronic respiratory conditions are prolonged ailments that affect the lungs and airways, leading to continuous breathing issues. The prevalence of these conditions can be attributed to several factors, including an aging population, lifestyle choices and smoking, genetic and occupational influences, and environmental pollution. Synagis (palivizumab) works to prevent severe respiratory syncytial virus (RSV) infections in at-risk infants and children, thereby reducing complications and exacerbations in those with chronic respiratory conditions. For instance, in June 2025, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that chronic respiratory diseases impact more than 80 million individuals, with many more undiagnosed, according to a new WHO and European Respiratory Society report. Thus, the rising prevalence of chronic respiratory conditions is driving the expansion of the synagis market.

What Are The Main Segments Within The Synagis Market Segment Structure?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

Which Trends Are Shaping The Synagis Market?

Major companies operating in the Synagis market are focusing on obtaining drug approvals to provide preventive therapy for respiratory syncytial virus (RSV), addressing a significant unmet medical need. Drug approval is the regulatory process in which authorities evaluate a drug’s safety, efficacy, and quality based on clinical trial data before authorizing it for use. For instance, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical company, obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventive therapy for RSV. This injection is available as palivizumab 100 mg/ml in single-dose vials of 50 mg/0.5 ml and 100 mg/ml for intramuscular administration. Palivizumab is indicated for infants born at =35 weeks gestation, children requiring treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This approval represents the first preventive therapy for RSV available in India.

Who Are The Companies Participating In The Synagis Market?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Get The Full Synagis Market Report:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

Which Region Accounts For The Largest Portion Of The Synagis Market?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Synagis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

Browse Through More Reports Similar to the Global Synagis Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Synagis Market In 2026 And What Value Is Projected For 2030?

The historical growth can be linked to a rise in RSV infection cases among infants, coupled with increasing recognition of preventive monoclonal antibody treatments. Further contributing factors include the expansion of neonatal intensive care units, the provision of reimbursement for RSV preventive measures, and the regulatory clearances granted for pediatric biological drugs.

The market expansion during the projected period is driven by several factors, including heightened investments in advanced RSV prevention treatments, a growing emphasis on long-acting monoclonal antibodies, an increase in biologic manufacturing capabilities, rising expenditure on pediatric healthcare, and the wider adoption of precision immunotherapy techniques.

Significant developments anticipated in the forecast period encompass the increasing use of monoclonal antibody-based RSV prophylaxis, a greater focus on preventive pediatric immunotherapies, the expansion of cold-chain dependent biologic distribution networks, an intensified commitment to protecting high-risk infants, and improved scalability in the production of biologics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Synagis Market?

The future expansion of the Synagis market is anticipated to be driven by the growing incidence of chronic respiratory conditions. These are long-term illnesses affecting the lungs and airways, resulting in persistent breathing difficulties. Several elements contribute to the widespread occurrence of chronic respiratory conditions, including an aging demographic, choices related to smoking and lifestyle, genetic and work-related factors, and environmental contaminants. Synagis (palivizumab) offers protection against severe respiratory syncytial virus (RSV) infections in vulnerable infants and children, thereby mitigating complications and flare-ups in individuals with chronic respiratory issues. For instance, in June 2025, the World Health Organization (WHO), a specialized UN agency based in Switzerland, reported that chronic respiratory diseases impact over 80 million people, with many cases remaining undiagnosed, as per a joint WHO and European Respiratory Society report. Consequently, the rising prevalence of chronic respiratory conditions is fueling the growth of the Synagis market.

What Are The Key Segments Of The Synagis Market?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

What Key Trends Are Influencing The Development Of The Synagis Market?

Companies operating in the Synagis market are primarily focused on achieving drug approvals to deliver preventive treatments for respiratory syncytial virus (RSV), thereby addressing a significant unfulfilled medical requirement. Drug approval constitutes the regulatory framework through which authorities evaluate a drug’s safety, effectiveness, and quality, based on data from clinical trials, prior to authorizing its use. For instance, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical company, obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventative therapy for RSV. This injection is supplied as palivizumab 100 mg/ml in single-dose vials of 50 mg/0.5 ml and 100 mg/ml for intramuscular administration. Palivizumab is prescribed for infants born at =35 weeks gestation, children needing treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This endorsement signifies the first preventive therapy for RSV to become available in India.

Who Are The Leading Companies Operating In The Synagis Market?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Read the full synagis market report here:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

What Are The Leading Geographic Regions In The Synagis Market?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Synagis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp

Browse Through More Reports Similar to the Global Synagis Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the synagis market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Synagis Market be in 2030 compared with 2026?

The expansion observed during the historic period stems from a rise in the incidence of RSV infections among infants, a heightened awareness of preventive monoclonal therapies, the broader availability of neonatal intensive care units, the provision of reimbursement for RSV prophylaxis, and regulatory endorsements for pediatric biologics.

The growth anticipated in the forecast period stems from escalating investments in next-generation RSV prevention therapies, a heightened emphasis on long-acting monoclonal antibodies, an expansion of biologic manufacturing capabilities, increasing pediatric healthcare spending, and the wider embrace of precision immunotherapy approaches.

Major developments projected for the forecast period encompass a rising adoption of monoclonal antibody-based RSV prophylaxis, an increased focus on preventive pediatric immunotherapies, the expansion of cold-chain dependent biologic distribution networks, a growing commitment to protecting high-risk infants, and enhanced manufacturing scalability for biologics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

What Drivers Are Guiding Growth Patterns In The Synagis Market?

The rising occurrence of chronic respiratory conditions is anticipated to fuel the expansion of the Synagis market moving forward. These conditions are long-term illnesses affecting the lungs and airways, resulting in ongoing breathing difficulties. Various elements contribute to the prevalence of chronic respiratory conditions, such as an aging population, smoking and lifestyle decisions, genetic and occupational factors, and environmental contamination. Synagis (palivizumab) is crucial for preventing severe respiratory syncytial virus (RSV) infections in vulnerable infants and children, thereby mitigating complications and exacerbations in individuals with existing chronic respiratory conditions. For example, in June 2025, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations, indicated that chronic respiratory diseases impact more than 80 million people, with a significant number remaining undiagnosed, as per a joint WHO and European Respiratory Society report. Consequently, the growing prevalence of chronic respiratory conditions is a key driver for the Synagis market. Synagis Market Driver: Impact Of Increasing Healthcare Expenditure On The Growth Of The Market

Which Segments Are Driving Activity In The Synagis Market?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

What Long-Term Trends Are Expected To Shape The Future Of The Synagis Market?

Key companies within the Synagis market are primarily focused on obtaining drug approvals to deliver preventive therapy for respiratory syncytial virus (RSV), thereby addressing a significant unmet medical requirement. Drug approval is defined as the regulatory procedure wherein authorities assess a drug’s safety, efficacy, and quality, utilizing clinical trial data before granting authorization for its usage. For instance, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical organization, secured approval from the Central Drugs Standard Control Organisation (CDSCO) to commercialize palivizumab, which serves as a preventive therapy for RSV. This injection is presented as palivizumab 100 mg/ml in single-dose vials of 50 mg/0.5 ml and 100 mg/ml, designed for intramuscular administration. Palivizumab is prescribed for infants born at =35 weeks gestation, children who require treatment for bronchopulmonary dysplasia (BPD), and individuals diagnosed with hemodynamically significant congenital heart disease (CHD). This approval signifies the inaugural preventive therapy for RSV to become available in India.

Which Leading Companies Dominate The Synagis Market Share?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

How Does The Synagis Market Perform Across Major Global Regions?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Synagis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp

Browse Through More Reports Similar to the Global Synagis Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Synagis Market Grown from 2024 to 2025?

In recent times, the synagis market size has experienced an XX (HCAGR). The market, valued at $XX million in 2024, is projected to reach $XX million in 2025, growing at a compound annual rate (CAGR) of XX%. The driving factors for this surge during the historical period include escalating expenditures on chronic illnesses, increased investment in research and development activities, rising disease burden, increased rate of hospitalizations, and an augmenting prevalence of chronic respiratory ailments.

What Growth Rate Is Anticipated for the Synagis Market in the Coming Years?

Expectations are set for the synagis market size to witness a XX (FCAGR) surge in the coming years. By 2029, its growth is projected to reach $XX million at a XX% compound annual growth rate (CAGR). Such growth within the forecast period could be due to mounting R&D expenses, increased prevalence of RSV, rising demand for personalized healthcare and telemedicine services, an expanding elderly population, and a swelling pediatric population in developing markets. During the forecast period, the market would be characterized by significant trends such as advancement in RSV therapy, biosimilar development, clinical trial results, treatment improvements, regulatory approvals, and the launch of combination vaccines.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

Who Are the Leading Companies in the Synagis Market?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

What Are the Key Drivers of the Synagis Market?

The surge in chronic respiratory conditions is predicted to spur the synagis market’s growth. These prolonged diseases affect the lungs and airways, causing continuous breathing issues. The rise in these conditions is connected to several factors such as an aging populace, smoking habits, lifestyle choices, genetic and professional factors, and environmental pollution. Synagis (palivizumab) is utilized to prevent serious respiratory syncytial virus (RSV) infections in infants and children who are at high risk, thus reducing complications in those with chronic respiratory conditions. For example, a report issued by Public Health Scotland revealed that in December 2023, doctor-diagnosed asthma prevalence escalated from 16% in 2021 to 17% in 2022. Consequently, the rise in chronic respiratory conditions is driving the expansion of the synagis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp

What Are the Key Market Segments in the Synagis Industry?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis; Premature Infants With Bronchopulmonary Dysplasia (BPD); Congenital Heart Disease (CHD); Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL); 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors; Online Retailers

4) By End-User: Pediatric; Adults

What Are the Latest Trends in the Synagis Market?

A major shift in the synagis market is securing regulatory approval for drugs, thus paving the way for a much-anticipated preemptive treatment for respiratory syncytial virus. Drug approval entails the review and authorization of a new drug for sale and utilization by regulatory bodies, confirming its safety, effectiveness, and quality through clinical trial data. For example, AstraZeneca Pharma India Ltd., an Indian biopharmaceutical firm, received the green light from the Central Drugs Standard Control Organisation (CDSCO) in September 2023 to market palivizumab, a preemptive treatment for respiratory syncytial virus (RSV). This encompasses the palivizumab 100 mg/ml injection, obtainable in 50 mg/0.5 ml and 100 mg/ml single-dose vials for intramuscular use. Palivizumab is seen as a possible treatment for infants born 35 weeks into gestation or less, children in need of bronchopulmonary dysplasia (BPD) treatment, and those suffering from hemodynamically significant congenital heart disease (CHD). This endorsement represents a crucial stride in enhancing RSV care in India since it is the country’s first available preventive therapy for RSV.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

What Are the Key Regional Markets in the Synagis Industry?

North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20304

This Report Delivers Insight On:

1. How big is the synagis market, and how is it changing globally?

2. Who are the major companies in the synagis market, and how are they performing?

3. What are the key opportunities and risks in the synagis market right now?

4. Which products or customer segments are growing the most in the synagis market?

5. What factors are helping or slowing down the growth of the synagis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Estimated Market Size of the Synagis Market In 2029?

In recent times, the synagis market has witnessed a XX (HCAGR) increase. The market that was valued at $XX million in 2024 is expected to expand to $XX million in 2025, marking a compound annual growth rate (CAGR) of XX%. The expansion over the historic period can be traced back to factors such as the rise in expenditure for chronic diseases, an upsurge in investment for research and development, an escalation in disease burden, a surge in hospital admissions, and the growing occurrence of chronic respiratory disorders.

Looking forward, the Synagis market is predicted to experience an XX (FCAGR) increase over the next several years, reaching a value of $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. Various factors are anticipated to contribute to this growth in the forecast period and these include the amplification in R&D spending, an increased incident rate of RSV, rising demand for personalized care and telemedicine, an aging population, and a growing pediatric demographic in emerging markets. Key trends expected to shape the market in the forecast period consist of progress in RSV treatment, the expansion of biosimilars, clinical trial results, treatment advances, regulatory approvals, and the launching of combination vaccines.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

What Are the Core Market Drivers Propelling Growth in the Synagis Industry?

Escalating occurrences of chronic respiratory illnesses are anticipated to boost the advancement of the synagis market in the future. Such long-term diseases strike the lungs and respiratory tract, leading to perpetual respiratory difficulties. The emergence of these conditions is influenced by many factors, like an aging demographic, lifestyle and smoking habits, hereditary and employment-related influences, and exposure to pollutants. Synagis (palivizumab) aids in warding off severe respiratory syncytial virus (RSV) infections in infants and kids who are at high risk, minimizing complications and flare-ups in individuals suffering from chronic respiratory diseases. For instance, a report by Public Health Scotland, an organization under the Scottish government, revealed in December 2023 that the presence of asthma diagnosed by doctors had risen from 16% in 2021 to 17% in 2022. Hence, the escalating incidences of chronic respiratory illnesses are fueling the expansion of the synagis market.

How Is the Synagis Market Segmented?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis; Premature Infants With Bronchopulmonary Dysplasia (BPD); Congenital Heart Disease (CHD); Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL); 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors; Online Retailers

4) By End-User: Pediatric; Adults

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp

Which Regions Are Driving the Next Phase of the Synagis Market Growth?

North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Synagis Market?

The primary trend in the synagis market pertains to achieving official drug authorization, to establish a long-anticipated preventive treatment for respiratory syncytial virus. Drug endorsement involves the assessment and approval of a novel drug for commercial sale and application, by verification authorities, confirming its safety, effectiveness, and quality as per clinical trial data. For instance, AstraZeneca Pharma India Ltd., a biopharmaceutical firm based in India, received permission from the Central Drugs Standard Control Organisation (CDSCO) in September 2023 to distribute palivizumab, a prophylactic therapy for respiratory syncytial virus (RSV). This consent embraces the palivizumab 100 mg/ml injection, offered in 50 mg/0.5 ml and 100 mg/ml single-dose vial formats for intramuscular use. The treatment is suggested for newborns birthed at 35 weeks of gestation or less, patients needing treatment for bronchopulmonary dysplasia (BPD), and those suffering from hemodynamically significant congenital heart disease (CHD). This endorsement represents a significant milestone in enhancing RSV healthcare in India, being the country’s first available preventive therapy for RSV.

View the full report here:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

How Is the Synagis Market Defined and What Are Its Core Parameters?

Synagis (palivizumab) is a medication used to prevent serious lower respiratory tract infections caused by the respiratory syncytial virus (RSV) in high-risk infants and children. It is a monoclonal antibody that works by binding to the RSV virus, preventing it from entering and infecting cells in the respiratory system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20304

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of the Synagis Market?

The increasing prevalence of chronic respiratory conditions is expected to propel the growth of the synagis market going forward. Chronic respiratory conditions are prolonged illnesses that impact the lungs and airways, leading to ongoing breathing problems. The prevalence of chronic respiratory conditions can be attributed to several factors, including an aging population, smoking and lifestyle choices, genetic and occupational factors, and environmental pollution. Synagis (palivizumab) prevents severe respiratory syncytial virus (RSV) infections in high-risk infants and children, reducing complications and exacerbations in those with chronic respiratory conditions. For instance, in December 2023, according to a report published by Public Health Scotland, a Scotland-based government organization, the prevalence of doctor-diagnosed asthma was 16% in 2021 and increased to 17% in 2022. Therefore, the increasing prevalence of chronic respiratory conditions is driving the growth of the synagis market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

How Will the Growth Rate of theSynagis Market Impact Industry Trends by 2034?

The synagis market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increasing spending on chronic illnesses, increase in research and development investment, rising disease burden, increasing hospitalization, and Increasing prevalence of chronic respiratory conditions.

The synagis market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising R&D expenditures, a rise in the prevalence of RSV, growing demand for personalized and telemedicine, a growing aging population, increasing pediatric population in emerging markets. Major trends in the forecast period include the development of RSV treatment, biosimilar development, clinical trial outcomes, advances in treatment and regulatory approvals, and the introduction of combination vaccines.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20304

What Key Market Trends and Innovations Are Shaping the Future of theSynagis Industry?

The key trend in the synagis market is obtaining drug approval by authorities to gain a long-awaited preventive therapy for respiratory syncytial virus. Drug approval is the process by which regulatory authorities evaluate and authorize a new drug for sale and use, ensuring its safety, efficacy, and quality based on clinical trial data. For instance, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical company, obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventive therapy for respiratory syncytial virus (RSV). This injection covers the palivizumab 100 mg/ml injection, which is available in 50 mg/0.5 ml and 100 mg/ml presentations in single-dose vials for intramuscular administration. Palivizumab is indicated for use in infants born at 35 weeks of gestation or less, children requiring treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This approval marks an important step in improving RSV care in India, as it is the first preventive therapy for RSV available in the country.

Which Companies Are Leading the Charge in Expanding theSynagis Market Growth?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

How is the Global Synagis Market Segemented?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis; Premature Infants With Bronchopulmonary Dysplasia (BPD); Congenital Heart Disease (CHD); Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL); 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors; Online Retailers

4) By End-User: Pediatric; Adults

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp

Which Geographics are Influencing the Growth of the Synagis Market?

North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Synagis Market 2025, By The Business Research Company:

Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025

https://thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Respiratory Disposables Global Market Report 2025

https://thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2025

https://thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the synagis market grown in recent years?

In recent times, the synagis market has experienced a XX (HCAGR) expansion. By 2024, it is projected to be worth $XX million, with an anticipated growth to $XX million in 2025, translating to a compound annual growth rate (CAGR) of XX%. The growth observed during the historical period is largely due to amplified expenditures on chronic diseases, escalated investments in research and development, growing disease loads, increased hospital admissions, and the rising incidence of chronic respiratory conditions.

How is the synagis market size expected to evolve during the forecast period?

In the upcoming years, the Synagis market is forecasted to experience an XX (FCAGR) increase. By 2029, it is projected to swell to $XX million with an annual compound growth rate (CAGR) of XX%. The surge during the predicted period can be credited to multiple factors. These include escalating research and developmental expenditures, an elevated prevalence of RSV, higher demands for personalized and telemedicine, a burgeoning aged population, and the expansion of the pediatric population in developing markets. The forecast period will also witness several significant trends, such as breakthroughs in RSV treatment, the evolution of biosimilars, outcomes of clinical trials, progress in treatment protocols, a string of regulatory approvals, and the launch of combination vaccines.

Get your synagis market report here!

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

Which key drivers are propelling the synagis market’s growth?

The burgeoning rate of chronic respiratory ailments is anticipated to boost the expansion of the synagis market in the future. Chronic respiratory disorders are enduring diseases that affect the lungs and air passages, resulting in persistent breathing difficulties. The occurrence of these chronic respiratory conditions can be linked to a variety of aspects, including an aging demographic, smoking and lifestyle habits, genetic and work-related influences, and environmental contamination. Synagis (palivizumab) serves to prevent severe respiratory syncytial virus (RSV) infections in children and infants at high risk, decreasing the risk of complications and the worsening of chronic respiratory conditions. For instance, as per a report circulated by Public Health Scotland, a government organization based in Scotland, the recorded prevalence of asthma diagnosed by doctors was 16% in 2021 and spiked to 17% in the subsequent year, 2022. Consequently, the rising prevalence of chronic respiratory conditions is fuelling the growth of the synagis market.

What are the market segments in the synagis industry?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis; Premature Infants With Bronchopulmonary Dysplasia (BPD); Congenital Heart Disease (CHD); Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL); 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors; Online Retailers

4) By End-User: Pediatric; Adults

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

Which leading companies are shaping the growth of the synagis market?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

What key trends are currently impacting the synagis market’s development?

A significant trend in the Synagis sector involves securing drug authorization from regulatory bodies in order to offer much-needed preventive treatment for the respiratory syncytial virus. This approval process allows a new drug to be sold and used after it has been evaluated and confirmed to be safe, effective, and of high quality using clinical trial findings. To illustrate, AstraZeneca Pharma India Ltd., an established biopharmaceutical company from India, received approval from the Central Drugs Standard Control Organisation (CDSCO) in September 2023. This allowed them to start selling palivizumab, a preventive treatment for the respiratory syncytial virus (RSV). The permitted product, a injection called palivizumab 100 mg/ml, is supplied in 50 mg/0.5 ml and 100 mg/ml doses in single-use vials for intramuscular administration. It is recommended to be used in infants born at or before 35 weeks of gestation, children who need treatment for bronchopulmonary dysplasia (BPD), and those suffering from clinically significant congenital heart disease (CHD). This groundbreaking approval signifies a key milestone in enhancing RSV healthcare in India because it is the country’s first available RSV preventive treatment.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20304

Which geographic areas are influencing the growth of the synagis market?

North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025

https://thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Respiratory Disposables Global Market Report 2025

https://thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2025

https://thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: